The information on this page applies only to the United States
One of Valeant’s areas of focus to drive growth in the U.S. is podiatry, which began with the acquisition of Pedinol Pharmacal, Inc. in 2012, a podiatry-focused, privately-owned specialty pharmaceutical company. The Pedinol business, with more than 85 years of experience, remains a strong fit alongside Valeant’s dermatology franchise and a key component as Valeant continues to expand into this market segment.
Additionally, in 2014 Valeant launched two new prescription pharmaceutical products that are having a significant adoption in the podiatry/dermatology market. Luzu® (luliconazole) Cream, 1% is indicated for the topical treatment of several conditions, including athlete’s foot, a common skin disease caused predominately by dermatophyte fungi. Luzu is the first safe and effective product indicated for daily use over a one-week period, an alternative to other options that require two weeks of treatment.
The second product is Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis, a common and destructive nail infection caused predominantly by dermatophyte fungi. Upon its launch, Jublia represented the first new topical onychomycosis treatment approved in more than a decade. An effective topical therapy like Jublia is a logical treatment option to avoid drug interactions and systemic side effects.